bluebird bio (BLUE) to Release Quarterly Earnings on Tuesday

bluebird bio (NASDAQ:BLUE) will be issuing its quarterly earnings data after the market closes on Tuesday, February 20th. Analysts expect the company to announce earnings of ($1.68) per share for the quarter.

Shares of bluebird bio (BLUE) opened at $197.50 on Tuesday. bluebird bio has a 1 year low of $73.95 and a 1 year high of $222.03. The company has a market cap of $9,050.00, a PE ratio of -28.17 and a beta of 2.07.

BLUE has been the topic of several recent research reports. Wedbush reiterated an “outperform” rating and issued a $174.00 price objective (up from $135.00) on shares of bluebird bio in a research report on Thursday, November 2nd. Evercore ISI upgraded shares of bluebird bio from an “in-line” rating to an “outperform” rating and set a $102.00 target price on the stock in a report on Monday, October 16th. BMO Capital Markets upped their target price on shares of bluebird bio from $134.00 to $162.00 and gave the company a “buy” rating in a report on Monday, October 30th. Maxim Group set a $170.00 target price on shares of bluebird bio and gave the company a “buy” rating in a report on Friday, November 17th. Finally, BidaskClub lowered shares of bluebird bio from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 16th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. bluebird bio presently has a consensus rating of “Hold” and an average price target of $161.45.

In other news, insider Jason Cole sold 1,129 shares of the stock in a transaction dated Friday, January 5th. The shares were sold at an average price of $173.38, for a total transaction of $195,746.02. Following the transaction, the insider now directly owns 19,945 shares in the company, valued at approximately $3,458,064.10. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Nick Leschly sold 5,435 shares of the stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $173.38, for a total transaction of $942,320.30. Following the transaction, the chief executive officer now owns 171,009 shares in the company, valued at $29,649,540.42. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 200,280 shares of company stock worth $37,818,846. Insiders own 3.90% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “bluebird bio (BLUE) to Release Quarterly Earnings on Tuesday” was originally published by American Banking News and is owned by of American Banking News. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/02/13/bluebird-bio-blue-to-release-quarterly-earnings-on-tuesday.html.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Earnings History for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply